Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Track CELC with free AI briefings, catalyst countdowns, and dilution alerts.

CELC · Celcuity Inc.

Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.

$642.7M Cash on Hand
31.7mo Cash Runway
31.6% Short Interest
$150.85 Analyst Target (13)
Follow CELC by email Get an email when CELC reports key news in an SEC filing, pushes back a promised milestone, files for a stock offering, lands on the Downside Radar or has an FDA decision. Free, no account needed.

We send one confirmation email first. Only emails about CELC, unsubscribe in one click. Privacy

📣 What CELC Says Is Next

Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.

📄 Latest SEC Filings in Plain English

Each summary is written by AI from the filing itself, and one that names a number or a name the filing does not contain is not shown. Quarterly and annual reports are listed by period. Read the filing before acting on it.

🧪 Trial & FDA Catalysts

📊 Drug Pipeline

DrugIndicationMost advanced trialStatus
Gedatolisib
FDA approved Jul 2026 · Revtorpyk
Breast Cancer Phase 3 · NCT05501886 Active not recruiting
Doxorubicin HER2-negative Breast Cancer Phase 2 · NCT03412643 Unknown
Samotolisib (LY3023414) Endometrial Cancer Phase 2 · NCT03675893 Recruiting
Metformin Endometrial Cancer Phase 2 · NCT03675893 Recruiting
Weekly Paclitaxel HER2-negative Breast Cancer Phase 2 · NCT03412643 Unknown

Also used in these trials (approved or third-party drugs, not CELC's own candidates): Alpelisib, Palbociclib, Fulvestrant, Letrozole, Capmatinib, Cyclophosphamide, Darolutamide, Neratinib, Abemaciclib, Pertuzumab, Talazoparib, Trastuzumab.

Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it

💰 Cash Runway & Dilution Risk

CELC holds $642.7M in cash and short-term investments (as of Sep 30, 2026) and burns about $60.8M/quarter from operations, an estimated runway of 31.7 months at that rate (BioRadar estimate, not company guidance).

Dilution pressure: 10 · Low

Recent financing filings on SEC EDGAR:

Source: SEC EDGAR (XBRL cash flow and financing filings). Dilution Watch: every company ranked → · Get an alert when CELC files for a raise →

👥 Who Owns CELC

Insiders 18.4% Institutions (357 holders) 81.6% Public and other holders 0%
HolderTypeShares% of sharesAs of
BAKER BROS. ADVISORS LP
Former 10% owner
Insider 4,372,852 8.90% 2026-07-14
Brian F. Sullivan
Chief Executive Officer, Director · +1.50M options
Insider 3,200,983 6.52% 2026-08-14
Blackrock Inc. Institution (13F) 3,177,631 6.47% 2026-09-30
Perceptive Advisors LLC Institution (13G, 5%+) 3,160,200 6.43% 2025-12-31
RTW Investments, LP Institution (13G, 5%+) 3,039,621 6.19% 2026-03-31
Deerfield Management Company, L.P Institution (13F) 2,397,664 4.88% 2026-09-30
State Street Corporation Institution (13F) 2,056,176 4.19% 2026-09-30
Vanguard Capital Management LLC Institution (13F) 1,941,490 3.95% 2026-09-30
Point72 Asset Management, L.P. Institution (13F) 1,764,914 3.59% 2026-09-30
NEA Management Company, LLC Institution (13F) 1,710,561 3.48% 2026-09-30
Bank of America Corporation Institution (13F) 1,709,364 3.48% 2026-09-30
Morgan Stanley Institution (13F) 1,532,977 3.12% 2026-09-30

Share count 49,126,314 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the total held by all 13F filers (Yahoo Finance); the table lists the largest (13F quarter ending 2026-09-30). Sources have different dates, so the split is approximate. Source: SEC EDGAR.

📈 Recent Insider Activity (Form 4)

Trade dateInsiderTransactionSharesPriceOwned after
2026-10-07
filed 2026-10-09
Furcht Leo
Option exercise (M) 250 $7.60 12,780
2026-10-07
filed 2026-10-09
Furcht Leo
Option exercise (M) 250 – –
2026-10-01
filed 2026-10-05
GRYSKA DAVID W
Award (A) 893 – 893
2026-08-14
filed 2026-08-18
Hahne Vicky
Award (A) 16,000 – 37,808
2026-08-14
filed 2026-08-18
Sullivan Brian F.
Award (A) 80,000 – 1,450,199

Only open-market purchases (P) and sales (S) are trading decisions. Awards (A), option exercises (M) and tax withholding (F) are compensation mechanics. Source: SEC Form 4.

📅 Past FDA Decisions & Stock Reactions

DateDrugTypeRun-up 30dDecision 1dAfter 5d
2026-07-17 REVTORPYK™ (gedatolisib) NDA +0.1% +0.1% —
2026-05-01 — sNDA +6.3% +3.5% +7.7%

Browse all historical PDUFA outcomes →

Get the full CELC picture

The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for CELC and every other ticker you follow. Card required, cancel anytime.

Start 7-day free trial →

Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.